Literature DB >> 26527360

Elevated plasma aldosterone is an independent risk factor for erectile dysfunction in men.

Fei Wu1, Shanhua Mao1, Tianfang Yu2, Haowen Jiang1, Qiang Ding1, Gang Xu3.   

Abstract

INTRODUCTION: Erectile dysfunction (ED) and cardiovascular disease (CVD) share a great number of common risk factors. There is growing evidence that aldosterone, an independent CVD risk factor, is associated with ED. AIMS: The purpose of this study was to determine the relationship between plasma aldosterone and erectile dysfunction.
METHODS: This study recruited 287 participants, ranging from 18 to 84 years old; 217 were suffering from ED, diagnosed by the International Index of Erectile Function 5 (IIEF-5) scores. Based on IIEF-5 scores, patients were divided into one control group and three ED groups (mild ED; moderate ED; severe ED). MAIN OUTCOME MEASURES: The differences in principal characteristics, blood routine, sexual hormone, adrenal hormone, thyroid hormone, renal function, liver function and blood lipid were compared between ED and control groups.
RESULTS: Our study demonstrated that the difference of mean plasma aldosterone levels between ED group and the control group was statistically significant (P < 0.05). Stepwise logistic regression analysis of all the possible factors support the role of aldosterone as an independent risk factor for ED (OR 1.011; 95 % CI 1.003-1.018; P = 0.004). Similar statistical methods were applied to the comparison between moderate to severe ED group and control to mild ED group (OR 1.017; 95 % CI 1.009-1.024; P < 0.001). ROC curve and the area under the curve (0.718; 95 % CI 0.643-0.794; P < 0.001) were performed to assess the diagnostic effect and to compare the severity of risk with the known independent risk factors, such as age and cholesterol (0.704; 95 % CI 0.631-0.778; P < 0.001). When using a 374 pg/mL cut-off value from Youden index, the OR of ED group versus controls is 3.106 (95 % CI 1.458-6.617), while the OR of moderate to severe ED versus control and mild ED is 5.480 (95 % CI 3.108-9.662).
CONCLUSIONS: We determined that elevated plasma aldosterone concentration is an independent risk factor for ED. Our findings also indicate that the aldosterone, a well-recognized contributor to vascular injury, might be a potential bond between ED and CVD.

Entities:  

Keywords:  Aldosterone; Cardiovascular disease; Erectile dysfunction; Risk factors

Mesh:

Substances:

Year:  2015        PMID: 26527360     DOI: 10.1007/s00345-015-1723-0

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  51 in total

1.  A major role for the rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea.

Authors:  K Iizuka; A Yoshii; K Samizo; H Tsukagoshi; T Ishizuka; K Dobashi; T Nakazawa; M Mori
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

2.  Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway.

Authors:  K Chitaley; C J Wingard; R Clinton Webb; H Branam; V S Stopper; R W Lewis; T M Mills
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

3.  Stress management and erectile dysfunction: a pilot comparative study.

Authors:  I Kalaitzidou; M S Venetikou; K Konstadinidis; A K Artemiadis; G Chrousos; C Darviri
Journal:  Andrologia       Date:  2013-07-03       Impact factor: 2.775

4.  Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle.

Authors:  V Sauzeau; H Le Jeune; C Cario-Toumaniantz; A Smolenski; S M Lohmann; J Bertoglio; P Chardin; P Pacaud; G Loirand
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 5.  Nitric oxide/redox-based signalling as a therapeutic target for penile disorders.

Authors:  Arthur L Burnett; Biljana Musicki; Liming Jin; Trinity J Bivalacqua
Journal:  Expert Opin Ther Targets       Date:  2006-06       Impact factor: 6.902

6.  Erectile dysfunction in patients with hyper- and hypothyroidism: how common and should we treat?

Authors:  Gerasimos E Krassas; Kostas Tziomalos; Fotini Papadopoulou; Nikolaos Pontikides; Petros Perros
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

7.  cGMP-dependent protein kinase phosphorylates and inactivates RhoA.

Authors:  N Sawada; H Itoh; J Yamashita; K Doi; M Inoue; K Masatsugu; Y Fukunaga; S Sakaguchi; M Sone; K Yamahara ; T Yurugi; K Nakao
Journal:  Biochem Biophys Res Commun       Date:  2001-01-26       Impact factor: 3.575

8.  Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.

Authors:  Michele De Rosa; Stefano Zarrilli; Giovanni Vitale; Carolina Di Somma; Francesco Orio; Libuse Tauchmanova'; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

9.  Vascular risk factors and erectile dysfunction in a cohort of healthy men.

Authors:  A Ponholzer; C Temml; M Rauchenwald; S Madersbacher
Journal:  Int J Impot Res       Date:  2006-03-16       Impact factor: 2.896

Review 10.  The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction.

Authors:  Massimiliano Caprio; Caterina Mammi; Iris Z Jaffe; Maria-Christina Zennaro; Antonio Aversa; Michael E Mendelsohn; Andrea Fabbri; Giuseppe M C Rosano
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more
  2 in total

Review 1.  The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction.

Authors:  Fei Wu; Yun Lin; Qingyong Liu
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

2.  Aldosterone induces inflammatory cytokines in penile corpus cavernosum by activating the NF-κB pathway.

Authors:  Fei Wu; Zu-Quan Xiong; Shan-Hua Mao; Ji-Meng Hu; Jian-Qing Wang; Hao-Wen Jiang; Qiang Ding
Journal:  Asian J Androl       Date:  2018 Jan-Feb       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.